Biodynamik Strengthens Innovation With U.S. Issued Patents For Tissue Distraction And Automation Systems
Lake Forest, CA — October 2025 — The United States Patent and Trademark Office (USPTO) has officially granted patents covering Biodynamik’s patented technologies for tissue distraction and automation. This milestone underscores Biodynamik’s commitment to advancing innovative patented technologies.
These newly issued patents secure Biodynamik’s exclusive rights to its core systems that enable precise, automated tissue distraction. Under U.S. patent law, the grants provide Biodynamik with the right to exclude others from making, using, or selling these patented technologies throughout the United States, ensuring strong protection for its intellectual property portfolio.
The patented systems form the foundation of Biodynamik’s XT3 and AT3 platforms. “These patents validate the engineering and development that have gone into creating our platform,” said Johnny Chen, Founder and CEO of Biodynamik. “They strengthen our ability to bring these technologies to more patients worldwide, while continuing to advance our orthopedic technologies.”
About Biodynamik
Biodynamik, Inc. develops orthopedic external fixation systems. The XT3® System is FDA 510(k) cleared for fracture fixation, nonunion, transverse bone transport of the tibia, and the correction of bony or soft tissue defects and deformities in adult patients. Biodynamik is sponsoring the SMILE-TTT study (IDE G260049) of transverse tibial transport in patients with diabetic foot ulcers; this use is investigational.